An observational study in Cancer, Hospitalizations and Sarcopenia, sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Ankara Etlik City Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective observational study evaluated whether simple bedside assessments performed during an unplanned hospitalization were associated with short-term outcomes in adults with metastatic solid cancer. The assessments included handgrip strength, blood-based cachexia and inflammatory-metabolic indices, body composition measured by bioelectrical impedance analysis, and patient-reported and nutritional measures.
The primary outcome was death from any cause within 30 days of the index hospital admission. Additional outcomes were death from any cause within 90 days and the first unplanned hospital readmission within 30 days after live discharge. The study aimed to determine whether different bedside domains were associated with mortality and readmission and whether these associations differed across outcomes.
Participants received usual clinical care, and no treatment was assigned by the study.
This prospective observational cohort study was conducted in the medical oncology inpatient unit of Ankara Etlik City Hospital. Consecutive adults aged 18 years or older with histologically or cytologically confirmed metastatic solid cancer undergoing unplanned hospitalization were assessed for eligibility.
Study assessments were performed during the index hospitalization. Laboratory values used to calculate composite indices were obtained within the first 24 hours of admission. Handgrip strength testing, bioelectrical impedance analysis, patient-reported measures, and nutritional assessment were performed within the first 48 hours of admission and, whenever clinically feasible, before initiation of new inpatient therapeutic interventions.
Handgrip strength was measured using a calibrated hydraulic hand dynamometer with the patient seated, the elbow flexed at 90 degrees, and the wrist in a neutral position. Three measurements of the dominant hand were obtained at 60-second intervals, and the highest value was retained for analysis.
The two primary composite bedside exposures were the handgrip strength-cachexia index and the standardized C-reactive protein-triglyceride-glucose index. Body-composition measures obtained by bioelectrical impedance analysis included phase angle, fat-free mass, fat mass, skeletal muscle mass, and total body water. Patient-reported and nutritional assessments included the Functional Assessment of Cancer Therapy-General, the Strength, Assistance with walking, Rising from a chair, Climbing stairs, and Falls questionnaire, the Pittsburgh Sleep Quality Index, resting pain assessed using a visual analog scale, appetite impairment assessed using a visual analog scale, and the Patient-Generated Subjective Global Assessment.
The primary outcome was 30-day all-cause mortality measured from the date of index admission. Additional outcomes were 90-day all-cause mortality and the first unplanned inpatient readmission within 30 days after live discharge. Planned admissions for anticancer treatment, scheduled procedures, day-case therapy, emergency department visits without inpatient admission, and observation stays were not counted as unplanned readmissions.
The study evaluated whether cachexia-related, inflammatory-metabolic, body-composition, patient-reported, and nutritional bedside measures were associated with short-term mortality and unplanned readmission. The study was observational and did not assign or modify anticancer or supportive treatment.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 233 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 9, 2026. See what changed
The study population consisted of adults aged 18 years or older with histologically or cytologically confirmed metastatic solid cancer who underwent unplanned admission to the medical oncology inpatient unit of Ankara Etlik City Hospital. Consecutive eligible patients were enrolled during the recruitment period. Bedside assessments, including handgrip strength, bioelectrical impedance analysis, patient-reported measures, and nutritional assessment, were performed within the first 48 hours of index hospitalization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort consisted of adults aged 18 years or older with histologically or cytologically confirmed metastatic solid cancer undergoing unplanned hospitalization in the medical oncology inpatient unit. Bedside assessments, including handgrip strength, bioelectrical impedance analysis, patient-reported measures, and nutritional assessment, were performed within the first 48 hours of the index hospitalization. Participants were followed for 30-day all-cause mortality, 90-day all-cause mortality, and the first unplanned hospital readmission within 30 days after live discharge.
Other: Handgrip Strength Assessment
Handgrip strength was measured within the first 48 hours of the index hospitalization using a calibrated hydraulic hand dynamometer. Measurements were performed on the dominant hand with the patient seated, the elbow flexed at 90 degrees, and the wrist in a neutral position. Three measurements were obtained at 60-second intervals, and the highest value was retained for analysis. Measurement was deferred when acute injury or recent surgery involved the dominant upper extremity.
30-day All-Cause Mortality
All-cause mortality within 30 days of the index hospital admission. Mortality was assessed from the date of index admission using hospital records and structured follow-up. All enrolled participants were included in this outcome assessment.
Time frame: 30 days after index hospital admission
90-Day All-Cause Mortality
All-cause mortality within 90 days of the index hospital admission. Mortality was assessed from the date of index admission using hospital records and structured follow-up. All enrolled participants were included in this outcome assessment.
Time frame: 90 days after index hospital admission
30-Day Unplanned Hospital Readmission After Live Discharge
The first unplanned inpatient hospital readmission occurring within 30 days after live discharge from the index hospitalization. Emergency department visits or observation stays without inpatient admission and planned admissions for systemic anticancer treatment, day-case therapy, scheduled procedures, or other elective care were not considered unplanned readmissions. This outcome was evaluated among participants discharged alive from the index hospitalization.
Time frame: 30 days after live discharge from index hospitalization
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Nov 2025, 11 months.
Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's 11 months is below that.
Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Sep 2024 → Dec 2024, primary completion Mar 2025 → Nov 2025 and completion Mar 2025 → Jan 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.